Syntara
Syntara Limited is a clinical-stage drug development company focused on creating novel treatments for blood-related cancers and conditions linked to inflammation and fibrosis. Their expertise lies in amine oxidase inhibitors, targeting extracellular matrix dysfunction to develop medicines for diseases with high unmet needs. The company's lead candidate, amsulostat, is currently in Phase 2 trials for myelofibrosis.
Short position
Syntara (ASX:SNT) has 0.24% of its shares on issue reported as short positions as of 7 July 2026, or about 4,806,305 shares. Over the past 30 days that figure has risen 0.24 percentage points, and over 90 days it has risen 0.11 percentage points. SNT is classified in the Pharmaceuticals, Biotechnology & Life Sciences industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.
Price & short interest
Toggle series, zoom, and compare · ASIC daily, T+4Syntara (SNT) financials
Results, ratios and statements
Latest result
Year to 30 Jun 2026 (FY26) vs FY25, figures in AUD, the reporting currency
- Revenue
- $6.8MM (source: ASX (Markit))vs $7.5MM (source: ASX (Markit)) (FY25)
- ASX (Markit), as at 29 Sep 2026
- NPAT
- −$9.0MM (source: ASX (Markit))vs −$7.9M (FY25)
- ASX (Markit), as at 29 Sep 2026
- EPS (diluted)
- −$0.005vs −$0.005 (FY25)
- Yahoo Finance, as at 29 Sep 2026
- Rev YoY
- −8.6%FY
- EPS YoY
- n/aFY
- ASX (Markit)
Key ratios
Year to 30 Jun 2026 (FY); no balance sheet aligned with this period; prices to 9 Oct 2026
- Gross margin
- n/a
- Operating margin
- −243.0%
- Net margin
- −131.6%
- FCF margin
- −143.1%
- ROE
- n/a
- ROA
- n/a
- FCF conversion
- n/a
- Net debt (excl. leases)
- n/a
- Net debt / EBITDA
- n/a
- Current ratio
- n/a
- Interest cover
- −1,660.8×
- Cash dividends paid / net profit
- n/a
- Market cap
- n/a (no share count we can vouch for)
- P/E
- n/a
- P/B
- n/a (no share count we can vouch for)
Ratios use the reporting currency (AUD); market cap is in AUD. Sources: Yahoo Finance, ASX (Markit) and Derived: trailing 12 months at year end, as at 29 Sep 2026.
Financial statements
Figures in AUD, the reporting currency; Yahoo Finance unless marked
| Line item | FY26 | FY25 | FY24 | FY23 |
|---|---|---|---|---|
| Revenue | $6.8MM (source: ASX (Markit)) | $7.5MM (source: ASX (Markit)) | $5.4MM (source: ASX (Markit)) | $5.8M |
| Gross profit | n/a | n/a | n/a | $3.1M |
| Operating income | −$16.6MT (source: Derived: trailing 12 months at year end) | −$19.9M | −$19.5M | −$25.3M |
| EBITDA | −$9.5MT (source: Derived: trailing 12 months at year end) | −$12.0M | −$13.0M | −$9.3M |
| EBIT | −$9.6MT (source: Derived: trailing 12 months at year end) | −$12.2M | −$13.3M | −$11.1M |
| Interest expense | $10.0KT (source: Derived: trailing 12 months at year end) | $30.0K | $386.0K | $223.0K |
| Pretax income | −$9.6MT (source: Derived: trailing 12 months at year end) | −$12.3M | −$13.7M | −$11.4M |
| Tax | $0T (source: Derived: trailing 12 months at year end) | $0 | $0 | $0 |
| NPAT | −$9.0MM (source: ASX (Markit)) | −$7.9M | −$15.1M | −$11.4M |
| Net interest income | $85.0KT (source: Derived: trailing 12 months at year end) | $302.0K | −$297.0K | −$106.0K |
| EPS basic | −$0.005 | −$0.005 | −$0.016 | −$0.017 |
| EPS diluted | −$0.005 | −$0.005 | −$0.016 | −$0.017 |
| Shares | n/a | 1.62B | 1.19B | 719.6M |
- ASX (Markit)
- Derived: trailing 12 months at year end
Financial reports
The company's own filings, newest first
- Appendix 4E and Annual ReportAnnual Results27 Aug 2026via asx_announcements
- Quarterly Activities/Appendix 4C Cash Flow ReportQuarterly Report27 Jul 2026via asx_announcements
- Quarterly Activities/Appendix 4C Cash Flow ReportQuarterly Report30 Apr 2026via asx_announcements
- Half Year Report and Appendix 4DHalf Year Results26 Feb 2026via asx_announcements
- Quarterly Activities/Appendix 4C Cash Flow ReportQuarterly Report29 Jan 2026via asx_announcements
- Euroz Hartleys: SNT: Different Pathway, Same DestinationFinancial Report31 Dec 2025via crawler
- Presentation: Phase 2 study of SNT-5505 in myelofibrosisHalf Year Results31 Dec 2025via crawler
- Euroz Hartleys: A Scar-tacular OpportunityFinancial Report31 Dec 2025via crawler
- MST Access: Progressing on multiple frontsFinancial Report31 Dec 2025via crawler
- Bioshares Research NoteFinancial Report31 Dec 2025via crawler
Showing 10 of 37 reports